Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia

Trial Profile

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 30 Jun 2021 Results of post -hoc analysis from NCT00404573, NCT01104779, NCT00694707, NCT01104766, NCT01104792, NCT00839852, NCT01412060, EudraCT 2012-005485-36 assessing safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia presented at the 15th World Congress of Biological Psychiatry
    • 15 Sep 2020 Results of post hoc pooled analysis (NCT01104766, NCT01104779, NCT00694707) assessing efficacy of cariprazine in the early stage of schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
    • 15 Sep 2020 Results of pooled post hoc analysis from NCT00404573, NCT01104766, NCT01104779, NCT00694707 assessing efficacy of cariprazine in the approved dose range versus placebo for reducing agitation and hostility in adult patients with an acute exacerbation of schizophrenia, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top